FDA approves extension for ACCRUFeR®

AI SummaryClose X

Shield Therapeutics plc announced that the US FDA has approved an expanded indication for ACCRUFeR® to include adolescents aged 10 years and older with iron deficiency, following positive results from a Phase 3 pediatric trial. The company plans to seek further approval for a new pediatric formulation, a ferric maltol suspension, for children aged 1 month and above, which could also serve as an alternative for adults unable to swallow capsules. This expansion significantly broadens the market for ACCRUFeR®, which is already the number one branded prescription oral iron in the US market.

Disclaimer*

UK 100

Latest directors dealings